Overall survival 2 years [clinicaltrials_resource:3c8dcd0e87a421e95be52beda5228e3d]
Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.
Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Overall survival 2 years [clinicaltrials_resource:3c8dcd0e87a421e95be52beda5228e3d]
Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.
Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented
Bio2RDF identifier
3c8dcd0e87a421e95be52beda5228e3d
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:3c8dcd0e87a421e95be52beda5228e3d
measure [clinicaltrials_vocabulary:measure]
Overall survival
time frame [clinicaltrials_vocabulary:time-frame]
description
Patients on the IAS arm should ...... resistance has been documented
identifier
clinicaltrials_resource:3c8dcd0e87a421e95be52beda5228e3d
title
Overall survival 2 years
@en
type
label
Overall survival 2 years [clinicaltrials_resource:3c8dcd0e87a421e95be52beda5228e3d]
@en